ridaforolimus + dalotuzumab

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Breast Cancer

Phase 1

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

CompletedNCT01220570

Merck Sharp & Dohme LLCBreast Cancer

Start: 2010-09-30End: 2012-12-31Updated: 2015-01-21

Phase 2

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

CompletedNCT01234857

Merck Sharp & Dohme LLCBreast Cancer

Start: 2010-09-17End: 2013-10-15Updated: 2017-05-31

Related Papers

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

2017-03-2115 citations